68 related articles for article (PubMed ID: 27499936)
41. The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study.
Kelly L; White S; Stone PC
Ann Oncol; 2007 Aug; 18(8):1395-9. PubMed ID: 17513884
[TBL] [Abstract][Full Text] [Related]
42. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients.
Suh SY; Ahn HY
Support Care Cancer; 2007 Jun; 15(6):613. PubMed ID: 17235502
[TBL] [Abstract][Full Text] [Related]
43. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer.
Guillem P; Triboulet JP
Dis Esophagus; 2005; 18(3):146-50. PubMed ID: 16045574
[TBL] [Abstract][Full Text] [Related]
44. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
45. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
McKeown DJ; Brown DJ; Kelly A; Wallace AM; McMillan DC
Br J Cancer; 2004 Dec; 91(12):1993-5. PubMed ID: 15570310
[TBL] [Abstract][Full Text] [Related]
46. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Nikolic N
J Cancer Res Clin Oncol; 2003 Feb; 129(2):114-22. PubMed ID: 12669236
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors in non-small cell lung cancer: a decade of progress.
Brundage MD; Davies D; Mackillop WJ
Chest; 2002 Sep; 122(3):1037-57. PubMed ID: 12226051
[TBL] [Abstract][Full Text] [Related]
48. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.
Scott HR; McMillan DC; Forrest LM; Brown DJ; McArdle CS; Milroy R
Br J Cancer; 2002 Jul; 87(3):264-7. PubMed ID: 12177792
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.
Galizia G; Orditura M; Romano C; Lieto E; Castellano P; Pelosio L; Imperatore V; Catalano G; Pignatelli C; De Vita F
Clin Immunol; 2002 Feb; 102(2):169-78. PubMed ID: 11846459
[TBL] [Abstract][Full Text] [Related]
50. Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years.
Geissbühler P; Mermillod B; Rapin CH
J Pain Symptom Manage; 2000 Aug; 20(2):93-103. PubMed ID: 10989247
[TBL] [Abstract][Full Text] [Related]
51. Acute-phase proteins and other systemic responses to inflammation.
Gabay C; Kushner I
N Engl J Med; 1999 Feb; 340(6):448-54. PubMed ID: 9971870
[No Abstract] [Full Text] [Related]
52. [The prognostic value of thrombocytosis in patients with primary lung cancer].
Pedersen LM; Milman N
Ugeskr Laeger; 1998 Jun; 160(26):3917-20. PubMed ID: 9656833
[TBL] [Abstract][Full Text] [Related]
53. Effect of recombinant interleukin-6 and thrombopoietin on isolated guinea pig bone marrow megakaryocyte protein phosphorylation and proplatelet formation.
Leven RM; Clark B; Tablin F
Blood Cells Mol Dis; 1997 Aug; 23(2):252-68. PubMed ID: 9410469
[TBL] [Abstract][Full Text] [Related]
54. Macrophage colony-stimulating factor enhances platelet recovery following cisplatin/carboplatin chemotherapy in ovarian cancer.
Suzuki M; Ohwada M; Aida I; Sato I; Tamada T
Gynecol Oncol; 1994 Jul; 54(1):23-6. PubMed ID: 8020834
[TBL] [Abstract][Full Text] [Related]
55. [Levels of VIIIR:Ag, VIII:C and fibrinogen in plasma of patients with lung cancer].
Ding YP; Feng BY; Ma ZF
Zhonghua Jie He He Hu Xi Za Zhi; 1994 Oct; 17(5):301-2, 319-20. PubMed ID: 7712574
[TBL] [Abstract][Full Text] [Related]
56. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
BMJ; 1995 Oct; 311(7010):899-909. PubMed ID: 7580546
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6.
Kimura H; Ishibashi T; Shikama Y; Okano A; Akiyama Y; Uchida T; Maruyama Y
Blood; 1990 Dec; 76(12):2493-500. PubMed ID: 2265245
[TBL] [Abstract][Full Text] [Related]
58. Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.
Badovinac S; Korsic M; Mursic D; Samarzija M; Cucevic B; Roglic M; Jakopovic M
J Thorac Dis; 2016 Jul; 8(7):1497-503. PubMed ID: 27499936
[TBL] [Abstract][Full Text] [Related]
59. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
60. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.
Pilkington G; Boland A; Brown T; Oyee J; Bagust A; Dickson R
Thorax; 2015 Apr; 70(4):359-67. PubMed ID: 25661113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
